Principles of use of antibacterial agents

Infectious Disease Clinics of North America

Volumn 18, Issue 3, 2004, Pages 435-450

  Hessen, Margaret Trexler ^a,b   Kaye, Donald ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PA 19010 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTACID AGENT; ANTIINFECTIVE AGENT; BETA LACTAM DERIVATIVE; CEFDITOREN; CEFEPIME; CEFONICID; CEFOPERAZONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GLYCOPEPTIDE; IMIPENEM; MACROLIDE; METHENAMINE; METRONIDAZOLE; NAFCILLIN; NALIDIXIC ACID; NITROFURANTOIN; PENICILLIN G; PROBENECID; QUINOLINE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BONE MARROW SUPPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; ENDOCARDITIS; HEARING IMPAIRMENT; HUMAN; HYPOKALEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHYSICAL EXAMINATION; REVIEW; SEIZURE; SIDE EFFECT; VESTIBULAR DISORDER;

ANTI-BACTERIAL AGENTS; HUMANS; INFECTION; MICROBIAL SENSITIVITY TESTS;

EID: 4043073517     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2004.04.002     Document Type: Review

References (68)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 26:1998;1-10. quiz 11-12
2. Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 43:2003;211-227
3. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 17:2003;503-528
4. Buijk S.E., Mouton J.W., Gyssens I.C., Verbrugh H.A., Bruining H.A. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med. 28:2002;936-942
5. Tod M., Lortholary O., Seytre D., et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother. 42:1998;849-856
6. Leeming J.P. Treatment of ocular infections with topical antibacterials. Clin Pharmacokinet. 37:1999;351-360
7. Smith A., Pennefather P.M., Kaye S.B., Hart C.A. Fluoroquinolones: place in ocular therapy. Drugs. 61:2001;747-761
8. Tamai I., Yamashita J., Kido Y., et al. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J Pharmacol Exp Ther. 295:2000;146-152
9. Barza M. Pharmacologic principles. Gorbach S., Bartlett J.G., Blacklow N.R. Infectious diseases, vol. 3. 2004;172-179 Lippincott Williams & Wilkins, Philadelphia
10. Gerding D.N., Hall W.H. The penetration of antibiotics into peritoneal fluid. Bull N Y Acad Med. 51:1975;1016-1019
11. Peterson L.R., Gerding D.N. Interaction of cephalosporins with human and canine serum proteins. J Infect Dis. 137:1978;452-457
12. Craig W.A., Vogelman B. Changing patterns of hospital infections: implications for therapy. Changing concepts and new applications of antibiotic pharmacokinetics. Am J Med. 77:1984;24-28
13. Wise R., Gillett A.P., Cadge B., Durham S.R., Baker S. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 142:1980;77-82
14. Chambers H.F., Mills J., Drake T.A., Sande M.A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 6:(Suppl 4):1984;S870-S874
15. Bryan L.E., Van den Elzen H.M. Streptomycin accumulation in susceptible and resistant strains of Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 9:1976;928-938
16. Bamberger D.M., Herndon B.L., Suvarna P.R. The effect of zinc on microbial growth and bacterial killing by cefazolin in a Staphylococcus aureus abscess milieu. J Infect Dis. 168:1993;893-896
17. Neu H.C. General concepts on the chemotherapy of infectious diseases. Med Clin North Am. 71:1987;1051-1064
18. Plorde J.J., Hovland D., Garcia M., Petersdorf R.G. Studies on the pathogenesis of meningitis. V. Action of penicillin in experimental pneumococcal meningitis. J Lab Clin Med. 65:1965;71-80
19. Quie P.G., Belani K.K. Coagulase-negative staphylococcal adherence and persistence. J Infect Dis. 156:1987;543-547
20. Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet. 358:2001;135-138
21. Carryn S., Van Bambeke F., Mingeot-Leclercq M.P., Tulkens P.M. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother. 46:2002;2095-2103
22. Pascual A., Ballesta S., Garcia I., Perea E.J. Uptake and intracellular activity of linezolid in human phagocytes and nonphagocytic cells. Antimicrob Agents Chemother. 46:2002;4013-4015
23. Carryn S., Chanteux H., Seral C., Mingeot-Leclercq M.P., Van Bambeke F., Tulkens P.M. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am. 17:2003;615-634
24. Van Bambeke F., Michot J.M., Tulkens P.M. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother. 51:2003;1067-1077
25. Bush L.M., Levison M.E. Antibiotic selection and pharmacokinetics in the critically ill. Crit Care Clin. 4:1988;299-324
26. Beringer P.M., Vinks A.A., Jelliffe R.W., Shapiro B.J. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 44:2000;809-813
27. Verbeeck R.K., Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci. 20:1998;183-192
28. Westphal J.F., Brogard J.M. Drug administration in chronic liver disease. Drug Saf. 17:1997;47-73
29. Rougier F., Claude D., Maurin M., et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother. 47:2003;1010-1016
30. Baciewicz A.M., Sokos D.R., Cowan R.I. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother. 37:2003;182-186
31. Carrizosa J., Kaye D. Antibiotic concentrations in serum, serum bactericidal activity, and results of therapy of streptococcal endocarditis in rabbits. Antimicrob Agents Chemother. 12:1977;479-483
32. Ebert S.C., Craig W.A. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 11:1990;319-326
33. Maglio D., Nightingale C.H., Nicolau D.P. Extended interval aminoglycoside dosing: from concept to clinic. Int J Antimicrob Agents. 19:2002;341-348
34. Craig W.A. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 17:2003;479-501
35. Maglio D., Nicolau D.P., Nightingale C.H. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am. 17:2003;563-577
36. Andes D., Craig W.A. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents. 19:2002;261-268
37. Tam V.H., McKinnon P.S., Akins R.L., Rybak M.J., Drusano G.L. Pharmacodynamics of cefepime in patients with gram-negative infections. J Antimicrob Chemother. 50:2002;425-428
38. Carbon C. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis. 27:1998;28-32
39. Periti P., Mazzei T. Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. J Chemother. 11:1999;11-27
40. Novelli A., Fallani S., Cassetta M.I., Arrigucci S., Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother. 14:2002;584-590
41. Schentag J.J., Nix D.E., Adelman M.H. Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. Drug Intelligence and Clinical Pharmacology: The Annals of Pharmacotherapy. 25:1991;1050-1057
42. Sanchez-Navarro A., Sanchez Recio M.M. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. Clin Pharmacokinet. 37:1999;289-304
43. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents. 19:2002;333-339
44. Jacobs M.R. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 7:2001;589-596
45. Jones R.N., Rubino C.M., Bhavnani S.M., Ambrose P.G. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother. 47:2003;292-296
46. Ambrose P.G., Bhavnani S.M., Owens R.C. Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am. 17:2003;529-543
47. Peric M., Browne F.A., Jacobs M.R., Appelbaum P.C. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin Ther. 25:2003;169-177
48. Mouton J.W. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am. 17:2003;579-598
49. Ambrose P.G., Bhavnani S.M., Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob Agents Chemother. 47:2003;1643-1646
50. Nicolau D.P. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 29:(Suppl 2):2001;11-15
51. Mouton J.W., Dudley M.N., Cars O., Derendorf H., Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents. 19:2002;355-358
52. Scaglione F., Mouton J.W., Mattina R., Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother. 47:2003;2749-2755
53. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother. 45:2001;2793-2797
54. Croisier D., Chavanet P., Lequeu C., et al. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother. 50:2002;349-360
55. Ernst E.J., Klepser M.E., Petzold C.R., Doern G.V. Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. Pharmacotherapy. 22:2002;463-470
56. Sanchez Navarro M.D., Coloma Milano C., Zarzuelo Castaneda A., Sayalero Marinero M.L., Sanchez-Navarro A. Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients. Clin Pharmacokinet. 41:2002;1213-1220
57. Nightingale C.H. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy. 20:2000;245-256
58. Moore R.D., Smith C.R., Lietman P.S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 149:1984;443-448
59. Jordan G.W., Kawachi M.M. Analysis of serum bactericidal activity in endocarditis, osteomyelitis, and other bacterial infections. Medicine (Baltimore). 60:1981;49-61
60. Weinstein M.P., Stratton C.W., Hawley H.B., Ackley A., Reller L.B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med. 83:1987;218-222
61. Liu P., Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am. 17:2003;599-613
62. Joukhadar C., Frossard M., Mayer B.X., et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 29:2001;385-391
63. Liu P., Muller M., Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents. 19:2002;285-290
64. Sorrell T.C., Collignon P.J. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 16:1985;235-241
65. Appel G.B., Neu H.C. The nephrotoxicity of antimicrobial agents (first of three parts). N Engl J Med. 296:1977;663-670
66. Kahlmeter G., Dahlager J.I. Aminoglycoside toxicity: a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 13:(Suppl A):1984;9-22
67. Whipple J.K., Ausman R.K., Franson T., Quebbeman E.J. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med. 19:1991;1480-1485
68. Fausti S.A., Henry J.A., Schaffer H.I., Olson D.J., Frey R.H., McDonald W.J. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis. 165:1992;1026-1032